{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,30]],"date-time":"2026-08-30T01:10:52Z","timestamp":1788052252458,"version":"build-2784847793"},"reference-count":43,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2018,8,15]],"date-time":"2018-08-15T00:00:00Z","timestamp":1534291200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Support Care Cancer"],"published-print":{"date-parts":[[2019,3]]},"DOI":"10.1007\/s00520-018-4400-1","type":"journal-article","created":{"date-parts":[[2018,8,15]],"date-time":"2018-08-15T04:30:21Z","timestamp":1534307421000},"page":"1109-1119","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":18,"title":["Cost-effectiveness analysis of olanzapine-containing antiemetic therapy for managing highly emetogenic chemotherapy in Southeast Asia: a multinational study"],"prefix":"10.1007","volume":"27","author":[{"given":"Suthan","family":"Chanthawong","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi Heng","family":"Lim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suphat","family":"Subongkot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandre","family":"Chan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rizka","family":"Andalusia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ros Suzanna","family":"Ahmad Bustamam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nathorn","family":"Chaiyakunapruk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,8,15]]},"reference":[{"key":"4400_CR1","doi-asserted-by":"publisher","first-page":"1055","DOI":"10.1038\/bjc.1997.507","volume":"76","author":"M Boer-Dennert de","year":"1997","unstructured":"de Boer-Dennert M, de Wit R, Schmitz PI, Djontono J, v Beurden V, Stoter G, Verweij J (1997) Patient perceptions of the side-effects of chemotherapy: the influence of 5HT3 antagonists. Br J Cancer 76:1055\u20131061","journal-title":"Br J Cancer"},{"key":"4400_CR2","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1006\/gyno.2002.6807","volume":"87","author":"CC Sun","year":"2002","unstructured":"Sun CC, Bodurka DC, Donato ML, Rubenstein EB, Borden CL, Basen-Engquist K, Munsell MF, Kavanagh JJ, Gershenson DM (2002) Patient preferences regarding side effects of chemotherapy for ovarian cancer: do they change over time? Gynecol Oncol 87:118\u2013128","journal-title":"Gynecol Oncol"},{"key":"4400_CR3","unstructured":"Schwartzberg L, Harrow B, Lal LS, Radtchenko J, Lyman GH (2015) Resource utilization for chemotherapy-induced nausea and vomiting events in patients with solid tumors treated with antiemetic regimens. Am Health Drug Benefits 8:273\u2013282"},{"key":"4400_CR4","doi-asserted-by":"crossref","unstructured":"Hesketh PJ, Grunberg SM, Gralla RJ, Warr DG, Roila F, de Wit R, Chawla SP, Carides AD, Ianus J, Elmer ME, Evans JK, Beck K, Reines S, Horgan KJ\u00a0(2003) The oral neurokinin-1 antagonist aprepitant for the prevention of chemotherapy-induced nausea and vomiting: a multinational, randomized, double-blind, placebo-controlled trial in patients receiving high-dose cisplatin\u2014the Aprepitant Protocol 052 Study Group. J Clin Oncol 21:4112\u20134119","DOI":"10.1200\/JCO.2003.01.095"},{"key":"4400_CR5","doi-asserted-by":"publisher","first-page":"3090","DOI":"10.1002\/cncr.11433","volume":"97","author":"S Poli-Bigelli","year":"2003","unstructured":"Poli-Bigelli S, Rodrigues-Pereira J, Carides AD, Julie Ma G, Eldridge K, Hipple A, Evans JK, Horgan KJ, Lawson F, On behalf of the Aprepitant Protocol 054 Study Group (2003) Addition of the neurokinin 1 receptor antagonist aprepitant to standard antiemetic therapy improves control of chemotherapy-induced nausea and vomiting. Results from a randomized, double-blind, placebo-controlled trial in Latin America. Cancer 97:3090\u20133098","journal-title":"Cancer"},{"key":"4400_CR6","doi-asserted-by":"publisher","first-page":"2381","DOI":"10.1007\/s00520-016-3075-8","volume":"24","author":"L Chiu","year":"2016","unstructured":"Chiu L, Chow R, Popovic M, Navari RM, Shumway NM, Chiu N, Lam H, Milakovic M, Pasetka M, Vuong S, Chow E, DeAngelis C (2016) Efficacy of olanzapine for the prophylaxis and rescue of chemotherapy-induced nausea and vomiting (CINV): a systematic review and meta-analysis. Support Care Cancer 24:2381\u20132392. https:\/\/doi.org\/10.1007\/s00520-016-3075-8","journal-title":"Support Care Cancer"},{"key":"4400_CR7","doi-asserted-by":"publisher","first-page":"4813","DOI":"10.1038\/srep04813","volume":"4","author":"XF Wang","year":"2014","unstructured":"Wang XF, Feng Y, Chen Y, Gao BL, Han BH (2014) A meta-analysis of olanzapine for the prevention of chemotherapy-induced nausea and vomiting. Sci Rep 4:4813. https:\/\/doi.org\/10.1038\/srep04813","journal-title":"Sci Rep"},{"key":"4400_CR8","doi-asserted-by":"publisher","first-page":"9587","DOI":"10.7314\/APJCP.2014.15.22.9587","volume":"15","author":"SY Wang","year":"2014","unstructured":"Wang SY, Yang ZJ, Zhang L (2014) Olanzapine for preventing nausea and vomiting induced by moderately and highly emetogenic chemotherapy. Asian Pac J Cancer Prev 15:9587\u20139592","journal-title":"Asian Pac J Cancer Prev"},{"key":"4400_CR9","doi-asserted-by":"publisher","first-page":"385","DOI":"10.2165\/00019053-199711050-00001","volume":"11","author":"M Johannesson","year":"1997","unstructured":"Johannesson M (1997) Avoiding double-counting in pharmacoeconomic studies. Pharmacoeconomics 11:385\u2013388","journal-title":"Pharmacoeconomics"},{"key":"4400_CR10","unstructured":"Wisit K, Tanyasaensook K, Thavorncharoensap M, Maneechavakajorn J, Chiaovit J (2013) Anti-emetic prophylaxis medication pattern for chemotherapy induced nausea vomiting (CINV) in patients with solid tumor at Rajavithi Hospital. Proceedings of The 2nd ASEAN Plus Three Graduate Research Congress Bangkok, Thailand 5-7 February 2014"},{"key":"4400_CR11","doi-asserted-by":"crossref","unstructured":"Konmun J, Danwilai K, Ngamphaiboon N, Sripanidkulchai B, Sookprasert A, Subongkot S (2014) A phase II randomized, double-blind placebo-controlled trial of an antiemetic, 6-gingerol in solid tumor patients receiving moderately to highly emetogenic adjuvant chemotherapy. J Clin Oncol 32:9647","DOI":"10.1200\/jco.2014.32.15_suppl.9647"},{"key":"4400_CR12","first-page":"1523","volume":"11","author":"BA Hassan","year":"2010","unstructured":"Hassan BA, Yusoff ZB (2010) Negative impact of chemotherapy on breast cancer patients QOL\u2014utility of antiemetic treatment guidelines and the role of race. Asian Pac J Cancer Prev 11:1523\u20131527","journal-title":"Asian Pac J Cancer Prev"},{"key":"4400_CR13","doi-asserted-by":"crossref","first-page":"385","DOI":"10.18553\/jmcp.2012.18.5.385","volume":"18","author":"A Chan","year":"2012","unstructured":"Chan A, Low XH, Yap KY (2012) Assessment of the relationship between adherence with antiemetic drug therapy and control of nausea and vomiting in breast cancer patients receiving anthracycline-based chemotherapy. J Manag Care Pharm 18:385\u2013394","journal-title":"J Manag Care Pharm"},{"key":"4400_CR14","unstructured":"Drug and Medical Supplies Information Center (DMSIC) Ministry of Public Health: unit prices of pharmaceutical products, Ministry of Public Health, 2015"},{"key":"4400_CR15","unstructured":"Health Intervention and Technology Assessment: HITAP Ministry of Public Health: standard cost list for health technology assessment, 2010"},{"key":"4400_CR16","doi-asserted-by":"publisher","unstructured":"Elamin EI, Ibrahim MI, Sulaiman SA, Muttalif AR (2008) Cost of illness of tuberculosis in Penang, Malaysia. Pharm World Sci 30:281\u2013286. https:\/\/doi.org\/10.1007\/s11096-007-9185-0","DOI":"10.1007\/s11096-007-9185-0"},{"key":"4400_CR17","unstructured":"Ministry of Health (2011) National Health and Morbidity Survey 2011"},{"key":"4400_CR18","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1016\/j.vhri.2012.03.002","volume":"1","author":"G Lopes","year":"2012","unstructured":"Lopes G, Burke T, Pellissier J, Zhang XH, Dedhiya S, Chan A (2012) Aprepitant for patients receiving highly emetogenic chemotherapy: an economic analysis for Singapore. Value in Health Regional 1:66\u201374","journal-title":"Value in Health Regional"},{"key":"4400_CR19","unstructured":"Ministry of Commerce Thailand: Consumer Price Index (CPI), 2016"},{"key":"4400_CR20","unstructured":"Bank Indonesia: Indonesia financial statistics: VIII. 1. Composite Consumer Price Index of 82 cities (2012=100). 2017"},{"key":"4400_CR21","unstructured":"Department of Statistics Malaysia: Consumer Price Index Malaysia December 2016, 2017"},{"key":"4400_CR22","unstructured":"Department of Statistics Singapore: Consumer Price Index (CPI), base year 2014 = 100, Annual, 2017"},{"key":"4400_CR23","unstructured":"Ettinger DS, Berger MJ, Aston J et al (2016) NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) Antiemesis Version 2.2016"},{"key":"4400_CR24","unstructured":"Chanthawong S, Subongkot S, Sookprasert A (2014) Effectiveness of olanzapine for the treatment of breakthrough chemotherapy induced nausea and vomiting. J Med Assoc Thai 97:349\u2013355"},{"key":"4400_CR25","unstructured":"Bank Indonesia: Foreign exchange reference rates: Jakarta interbank spot dollar rate USD-IDR, 2017"},{"key":"4400_CR26","unstructured":"Bank of Thailand: foreign exchange rates as of 10 February 2017: weighted-average interbank exchange rate, 2017"},{"key":"4400_CR27","unstructured":"Central Bank of Malaysia: Ringgit foreign exchange rates, 2017"},{"key":"4400_CR28","unstructured":"Monetary Authority of Singapore: exchange rates, 2017"},{"key":"4400_CR29","unstructured":"Health Intervention and Technology Assessment Program: Health Technology Assessment Guideline (ed 2). Nonthaburi, Health Intervention and Technology Assessment Program (HITAP), 2013"},{"key":"4400_CR30","unstructured":"Bank of Thailand: EC_EI_027 Thailand\u2019s macro economic indicators 1\/, Bank of Thailand, 2017"},{"key":"4400_CR31","unstructured":"Department of Statistics Malaysia: Malaysia @ a Glance: Malaysia, 2017"},{"key":"4400_CR32","unstructured":"Statistics Indonesia: economic growh of Indonesia of fourth quarter 2016, In (BPS) SI (ed). Jakarta, 2017"},{"key":"4400_CR33","unstructured":"Department of Statistics Singapore: national accounts: gross domestic product, 2017"},{"key":"4400_CR34","doi-asserted-by":"publisher","first-page":"542","DOI":"10.1016\/j.jpainsymman.2013.05.003","volume":"47","author":"N Mizukami","year":"2014","unstructured":"Mizukami N, Yamauchi M, Koike K, Watanabe A, Ichihara K, Masumori N, Yamakage M (2014) Olanzapine for the prevention of chemotherapy-induced nausea and vomiting in patients receiving highly or moderately emetogenic chemotherapy: a randomized, double-blind, placebo-controlled study. J Pain Symptom Manag 47:542\u2013550. https:\/\/doi.org\/10.1016\/j.jpainsymman.2013.05.003","journal-title":"J Pain Symptom Manag"},{"key":"4400_CR35","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1016\/j.suponc.2011.05.002","volume":"9","author":"RM Navari","year":"2011","unstructured":"Navari RM, Gray SE, Kerr AC (2011) Olanzapine versus aprepitant for the prevention of chemotherapy-induced nausea and vomiting: a randomized phase III trial. J Support Oncol 9:188\u2013195. https:\/\/doi.org\/10.1016\/j.suponc.2011.05.002","journal-title":"J Support Oncol"},{"key":"4400_CR36","doi-asserted-by":"crossref","unstructured":"Italian Group of Antiemetic Research (1995) Ondansetron versus granisetron, both combined with dexamethasone, in the prevention of cisplatin-induced emesis. Ann Oncol 6:805\u2013810","DOI":"10.1093\/oxfordjournals.annonc.a059320"},{"key":"4400_CR37","doi-asserted-by":"crossref","unstructured":"Ruff P, Paska W, Goedhals L, Pouillart P, Rivi\u00e8re A, Vorobiof D, Bloch B, Jones A, Martin C, Brunet R et al\u00a0(1994) Ondansetron compared with granisetron in the prophylaxis of cisplatin-induced acute emesis: a multicentre double-blind, randomised, parallel-group study. The Ondansetron and Granisetron Emesis Study Group. Oncology 51:113\u2013118","DOI":"10.1159\/000227321"},{"key":"4400_CR38","doi-asserted-by":"crossref","unstructured":"Seynaeve C, Schuller J, Buser K, Porteder H, Van Belle S, Sevelda P, Christmann D, Schmidt M, Kitchener H, Paes D et al (1992) Comparison of the anti-emetic efficacy of different doses of ondansetron, given as either a continuous infusion or a single intravenous dose, in acute cisplatin-induced emesis. A multicentre, double-blind, randomised, parallel group study. Ondansetron Study Group. Br J Cancer 66:192\u2013197","DOI":"10.1038\/bjc.1992.241"},{"key":"4400_CR39","doi-asserted-by":"publisher","first-page":"796","DOI":"10.1016\/j.jval.2012.06.012","volume":"15","author":"JJ Caro","year":"2012","unstructured":"Caro JJ, Briggs AH, Siebert U, Kuntz KM (2012) Modeling good research practices\u2014overview: a report of the ISPOR-SMDM modeling good research practices task force-1. Value Health 15:796\u2013803","journal-title":"Value Health"},{"issue":"6","key":"4400_CR40","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1200\/JGO.2016.005728","volume":"3","author":"A Chan","year":"2016","unstructured":"Chan A, Abdullah MM, Ishak WZBW, Ong-Cornel AB, Villalon AH, Kanesvaran R (2016) Applicability of the National Comprehensive Cancer Network\/Multinational Association of Supportive Care in Cancer Guidelines for Prevention and Management of Chemotherapy-Induced Nausea and Vomiting in Southeast Asia: a consensus statement. J Glob Oncol 3(6):801\u2013813. https:\/\/doi.org\/10.1200\/JGO.2016.005728","journal-title":"J Glob Oncol"},{"key":"4400_CR41","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1016\/j.jval.2013.02.002","volume":"16","author":"D Husereau","year":"2013","unstructured":"Husereau D, Drummond M, Petrou S, Carswell C, Moher D, Greenberg D, Augustovski F, Briggs AH, Mauskopf J, Loder E (2013) Consolidated health economic evaluation reporting standards (CHEERS) explanation and elaboration: a report of the ISPOR health economic evaluations publication guidelines good reporting practices task force. Value Health 16:231\u2013250","journal-title":"Value Health"},{"key":"4400_CR42","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1200\/JCO.2015.64.3635","volume":"34","author":"PJ Hesketh","year":"2016","unstructured":"Hesketh PJ, Bohlke K, Lyman GH, Basch E, Chesney M, Clark-Snow RA, Danso MA, Jordan K, Somerfield MR, Kris MG (2016) Antiemetics: American Society of Clinical Oncology focused guideline update. J Clin Oncol 34:381\u2013386. https:\/\/doi.org\/10.1200\/JCO.2015.64.3635","journal-title":"J Clin Oncol"},{"key":"4400_CR43","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1007\/s00520-016-3313-0","volume":"25","author":"J Herrstedt","year":"2017","unstructured":"Herrstedt J, Roila F, Warr D, Celio L, Navari RM, Hesketh PJ, Chan A, Aapro MS (2017) 2016 updated MASCC\/ESMO consensus recommendations: prevention of nausea and vomiting following high emetic risk chemotherapy. Support Care Cancer 25:277\u2013288","journal-title":"Support Care Cancer"}],"container-title":["Supportive Care in Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00520-018-4400-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00520-018-4400-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00520-018-4400-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,8,29]],"date-time":"2022-08-29T08:18:20Z","timestamp":1661761100000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00520-018-4400-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,8,15]]},"references-count":43,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2019,3]]}},"alternative-id":["4400"],"URL":"https:\/\/doi.org\/10.1007\/s00520-018-4400-1","relation":{},"ISSN":["0941-4355","1433-7339"],"issn-type":[{"value":"0941-4355","type":"print"},{"value":"1433-7339","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,8,15]]},"assertion":[{"value":"19 January 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 August 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 August 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}